Overcoming therapeutic resistance in colorectal cancer (CRC) remains a major clinical challenge, highlighting the need for strategies targeting epigenetic drivers. Targeted protein degradation emerged as a powerful approach to selectively eliminate disease-relevant proteins. We reported the development of two series of PROTACs based on the clinical-stage HDAC inhibitor entinostat, by recruiting either VHL or CRBN E3 ligases. Compounds 4b and 4h, representative of the two series of degraders, induced robust, time-dependent HDAC degradation with a clear-cut preference for HDAC3, leading to apoptosis and reduced viability in CRC models. The antitumor activity of the new degraders was proved in patient-derived colon cancer organoids and in the CRC CAM model. The role of acetylation in gene regulation and expression in CRC was investigated measuring p21 and stemness markers such as CD44 and LGR5. Collectively, these findings demonstrate that new degraders effectively target HDAC3 and exert anti-tumor activity across multiple CRC models.

Cursaro, I., Carullo, G., Cosenza, C., Heiß, A., Huebner, K., Song, J., et al. (2027). HDAC3 degradation to uncover therapeutic vulnerability in colorectal cancer. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 321(Pt 3) [10.1016/j.ejmech.2026.119463].

HDAC3 degradation to uncover therapeutic vulnerability in colorectal cancer

Cursaro, Ilaria;Carullo, Gabriele;Cosenza, Chiara;Gemma, Sandra;Butini, Stefania;Campiani, Giuseppe
2027-01-01

Abstract

Overcoming therapeutic resistance in colorectal cancer (CRC) remains a major clinical challenge, highlighting the need for strategies targeting epigenetic drivers. Targeted protein degradation emerged as a powerful approach to selectively eliminate disease-relevant proteins. We reported the development of two series of PROTACs based on the clinical-stage HDAC inhibitor entinostat, by recruiting either VHL or CRBN E3 ligases. Compounds 4b and 4h, representative of the two series of degraders, induced robust, time-dependent HDAC degradation with a clear-cut preference for HDAC3, leading to apoptosis and reduced viability in CRC models. The antitumor activity of the new degraders was proved in patient-derived colon cancer organoids and in the CRC CAM model. The role of acetylation in gene regulation and expression in CRC was investigated measuring p21 and stemness markers such as CD44 and LGR5. Collectively, these findings demonstrate that new degraders effectively target HDAC3 and exert anti-tumor activity across multiple CRC models.
2027
Cursaro, I., Carullo, G., Cosenza, C., Heiß, A., Huebner, K., Song, J., et al. (2027). HDAC3 degradation to uncover therapeutic vulnerability in colorectal cancer. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 321(Pt 3) [10.1016/j.ejmech.2026.119463].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1332355
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo